Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock

Key Points

• CFO Terrance Coyne sold 34,791 shares on April 28 at an average price of $49.78, totaling about $1.73 million, and the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
• The company declared a quarterly dividend of $0.235 per share (annualized $0.94) with an ex-dividend date of May 15 and a payment date of June 10, implying a yield of roughly 1.9%.
• RPRX recently beat EPS estimates ($1.46 vs. $1.33), trades near its 1‑year high (~$50) with a market cap of $28.9 billion, and carries an average analyst rating of Buy (average target $50.33; UBS target $57).

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of Royalty Pharma stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total value of $1,731,895.98. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Royalty Pharma Stock Performance

Shares of RPRX stock traded up $0.60 during mid-day trading on Thursday, reaching $50.09. The stock had a trading volume of 4,140,067 shares, compared to its average volume of 3,520,156. The business's fifty day moving average is $47.21 and its 200-day moving average is $42.31. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. The firm has a market cap of $28.89 billion, a price-to-earnings ratio of 37.10, a PEG ratio of 3.17 and a beta of 0.39. Royalty Pharma PLC has a 1-year low of $31.97 and a 1-year high of $50.47.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.33 by $0.13. The firm had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. On average, research analysts forecast that Royalty Pharma PLC will post 5.08 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a yield of 1.9%. The ex-dividend date is Friday, May 15th. Royalty Pharma's payout ratio is presently 69.63%.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of research reports. Wall Street Zen lowered shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. The Goldman Sachs Group reiterated a "buy" rating on shares of Royalty Pharma in a research note on Thursday, February 12th. TD Cowen reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, February 27th. Weiss Ratings upgraded shares of Royalty Pharma from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, February 12th. Finally, UBS Group increased their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a "buy" rating in a research note on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $50.33.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. LM Advisors LLC purchased a new stake in Royalty Pharma during the fourth quarter worth $26,000. Lloyd Advisory Services LLC. purchased a new stake in Royalty Pharma during the fourth quarter worth $30,000. Smartleaf Asset Management LLC boosted its stake in shares of Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 790 shares in the last quarter. Private Trust Co. NA grew its position in shares of Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 288 shares during the period. Finally, Blue Trust Inc. grew its position in shares of Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 437 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.